ASCO: Intermittent Docetaxel May be Option in mCRPC (CME/CE)

(MedPage Today) -- Chemo breaks well tolerated, with good 1-year survival
Source: MedPage Today Meeting Coverage - Category: Journals (General) Source Type: news